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ABSTRACT
Human papillomavirus (HPV) is widely known as a cause of cervical cancer (CC) and cervical intrae-
pithelial neoplasia (CIN). HPVs related to cancer express two main oncogenes, i.e. E6 and E7, considered
as tumorigenic genes; their integration into the host genome results in the abnormal regulation of cell
cycle control. Due to their peculiarities, these oncogenes represent an excellent target for cancer
immunotherapy. In this work the authors highlight the potential use of therapeutic vaccines as safe
and effective pharmacological tools in cervical disease, focusing on vaccines that have reached the
clinical trial phase. Many therapeutic HPV vaccines have been tested in clinical trials with promising
results. Adoptive T-cell therapy showed clinical activity in a phase II trial involving advanced CC
patients. A phase II randomized trial showed clinical activity of a nucleic acid-based vaccine in HPV16
or HPV18 positive CIN. Several trials involving peptide-protein-based vaccines and live-vector based
vaccines demonstrated that these approaches are effective in CIN as well as in advanced CC patients.
HPV therapeutic vaccines must be regarded as a therapeutic option in cervical disease. The synergic
combination of HPV therapeutic vaccines with radiotherapy, chemotherapy, immunomodulators or
immune checkpoint inhibitors opens a new and interesting scenario in this disease.
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Introduction
Human papillomavirus (HPV) causes one-third of infection-
associated cancers. Although prophylactic vaccines provide
protection against HPV-16 and HPV-18, the genotypes causing
about 70% of cervical cancer, vaccination programs are dis-
appointing in several countries, and many women remain at
risk of developing cervical cancer. Moreover, the frequency of
HPV-associated cancers continues to increase at anatomical
sites other than the cervix, such as vagina, vulva, oropharynx,
and anus, thus helping feed the problem [1].
HPV is a double-stranded DNA virus that exhibits unidirectional
transcription. To date, more than 200 HPV genotypes have been
identified, even if only few cause cancer [2] Six early proteins (E1,
E2, E4, E5, E6, and E7) and two late, capsid proteins (L1 and L2) are
synthesized by HPV during replication through the differentiating
strata of epithelia. HPV virus can infect the basal epithelial cells in
the cervical transformation zone, causing their proliferation and
leading to epithelial hyperplasia or papillomatosis. E5, E6, and E7
are considered oncoproteins and are responsible for continuous
cell proliferation, DNA amplification, and impairment of DNA
repair mechanisms, with consequent accumulation of mutations,
rearrangements, and aneuploidies. The integration of viral DNA
into the host cell genome in selected cases is a crucial step,
resulting in deletion of E2 gene and adjacent regions (frequently
E4, E5, and L2 genes). The E2 deletion, a transcriptional regulator
of E6 and E7, leads to overexpression of E6/E7 that, in turn, induce
degradation of p53 and pRB, respectively. In addition, E6/E7 alter
expression of genes involved in S phase of the cell cycle, interact
with p21 and p27 that inhibits cyclin-dependent kinases regulat-
ing the transition from G1 to S phase, and interfere with pro-
apoptotic functions of some proteins such as c-myc, BAK, p53.
As a consequence, this complicate and finely tuned process may
lead to malignant transformation [3–6].
Consequences of HPV persistent infection are squamous
intraepithelial lesions (cervical intraepithelial neoplasia, CIN)
that are considered as precursors of cancer, graded into three
progressive risk group according to the proportion of epithelium
affected by abnormalities: CIN1, CIN2, CIN3 [7]. CIN1 can evolve
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in a small percentage of cases into CIN2–3, with a continuous
proliferation and an increase in chromosomal instability reflected
by increasingly mitotic figures, nuclear abnormality and clumps
of pyknotic cells [8,9]. In CIN3, these cell alterations are distrib-
uted throughout the full thickness of epithelium rendering his-
tological diagnosis quite easy.
Currently, it is estimated that 32–43% of CIN2/3 lesions
undergo spontaneous regression [10,11]. However, we still
do not have prognostic biomarkers that can distinguish the
likelihood of regression at the individual patient level.
Standard treatment for patients with CIN2/3 is surgical excision
(cold knife conization or loop electrosurgical excision). It is to note
that a considerable morbidity is associated with CIN treatment
including low birth weight, pre-term births, increased deaths, and
more caesarian section [12]. Thus, other therapeutic options are
needed. Among the non-surgical hypothetical therapeutic options,
several immunotherapeutic strategies have been explored in pre-
clinical and clinical trials, with some promising results [13,14].
Prophylactic HPV vaccines act by inducing neutralizing antibo-
dies against the L1 capsid proteins of HPV-16 and HPV-18 [15,16],
whereas therapeutic vaccines generate cell-mediated HLA
restricted adaptive T-cell immunity for killing virus infected cells.
Since appreciable levels of L1/L2 capsid antigens are not
expressed by cervical cancer cells, therapeutic vaccines need tar-
gets other than L1/L2, and since HPV E6 and E7 are necessary for
the initiation andmaintenance of malignant transformation, these
antigens represent attractive targets for therapeutic vaccines.
Several therapeutic vaccines, employing vector-based peptide or
protein-based, nucleic acid-based, viral/bacterial vector based,
and cell-based therapeutic vaccines targeting the HPV-16 E6
and/or E7 antigens have been tested in order to increase viral
specific immune responses [17,18]. Achieving a valid immunother-
apy against HPV-related pathologies has to face several obstacles
including major histocompatibility complex (MHC) class I down-
regulation, impaired antigen-processing, homing of T-cell killer,
and immunosuppression due to Treg infiltration, and secretion of
immunosuppressive cytokines [14]. Immunosuppression is less
effective in pre-cancer lesions rendering more efficacious immu-
notherapeutic intervention. However, recent discovery of mono-
clonal antibodies against immune check-points has completely
changed the immunotherapy of tumors by altering the immuno-
suppressive milieu of cancer [19]. Pre-clinical data from mouse
models on large already established HPV tumors indicate the
extremely effectiveness of immunotherapy in combination with
immune check-point blockade [20,21].
In this review, we report preliminary results and ongoing stu-
dies on therapeutic vaccines in pre-invasive and invasive cervical
cancer, focusing on vaccines that have reached the clinical trial
phase. Table 1 summarizes the main characteristics of these trials,
while details on relevant ongoing clinical trials are reported in
Table 2. Figure 1 showsmethodologies for production anddelivery
of HPV therapeutic vaccines aswell as their immunological activity.
Cell-based approaches
Dendritic cell-based vaccines
Dendritic cells (DCs) have strong ability to initiate and control
T-cell response, being ideal candidates for immunotherapy stra-
tegies. They can be divided into DCs pulsed with peptides/
proteins, or transducedwithDNA or viral vectors encoding target
antigen. A pilot study was carried out in 15 advanced cervical
patients treated with autologous monocyte-derived DCs pulsed
with recombinant HPV-16 E7 or HPV-18 E7 oncoprotein, showing
T-cell response and good tolerability, but no objective responses
were observed [22]. Other studies used a DC vaccine pulsed with
recombinant HPV-16/18 E7 antigens and IL-2, or keyhole limpet
hemocyianin (an immunologic tracer molecule), with strong
immunological response but no clinical effect [23,24]. Since pre-
liminary reports with DC cancer vaccines consisting of ex vivo
generated DCs loaded with tumor antigens did not show clinical
responses in advanced cancer patients, the combination with
cytokine to favor DC maturation and antigen presentation have
been tested in various tumors [25–28]. Thirty-two patients with
HPV-16/18 positive advanced cervical cancer were treated with
HPV-16 E6 (arm A) or HPV E7 peptide (arm B) pulsed on periph-
eral blood mononuclear cells (PBMCs) cultured for 5–7 days in
GM-CSF and IL-4 (pre-immature dendritic cells), to obtain
immune response against the relevant peptide on both arms.
ELISPOT and 51Cr release assays showed immune response
against the relevant peptide in 63% of the patients in arm A
and in 58% of the patients in arm B. No objective responses were
observed, and treatment was well tolerated. The administration
of pre-immature DCs pulsed with HPV-16 E6 or E7 was feasible
and induced a specific immune response, thus deserving further
investigations [29].
Gene-transduced DCs vaccines represent a promising strat-
egy, since HLA restriction may be bypassed, and several pre-
clinical studies have been carried out with DC vaccines
transduced with adenoviral vector carrying a mutated E7 pro-
tein with encouraging results in animal models [30].
Cytokine-induced killer (CIK) cells, generated from PBMCs
by culturing in the presence of various cytokines, combined
with DCs through a co-culture of DC and CIK, have the advan-
tage of fast proliferation, high cytotoxicity and a broad tumor
killing spectrum [31]. In early cervical cancer, a phase II rando-
mized trial was performed in 79 surgery-treated, high-risk
cervical cancer patients. They received as adjuvant treatment
cisplatin alone versus cisplatin combined with DC–CIK cells.
The immune function was significantly improved in the experi-
mental arm (lymphocyte ratio and expression of perforin, GraB
and CD107a of PBMCs), and the cumulative recurrence rate in
the experimental arm was significantly lower than that in the
control arm [32].
Despite some promising results DC-based therapies have
several limitations, such as labor-intensive and expensive pro-
cedures and, moreover their short half-life and absence of
proliferation limit long-lasting immune response.
Tumor-cells-based vaccines
Tumor-cell-based vaccines comprise delivery of whole tumor
cells in order to stimulate immune system to recognize tumor-
associated antigens, and are often genetically modified in vitro
with genes encoding cytokines (IL-2, IL-12, GM-CSF) to
increase immune response [33–35]. At present, the use of
tumor cells (harvested from the patients) as vaccination is
not considered in CIN/early stages of the disease due to safety
concerns.
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Table 1. Main therapeutic vaccines for cervical pre-neoplastic lesions and cervical cancer.
Therapeutic agent Phase Disease No. of PTS
Immunological
effect
Clinical
effect Ref
Cell-based vaccines
Autologous monocyte-derived DCs pulsed with recombinant HPV-16 E7
or HPV-18 E7 oncoprotein
Pilot Stage IV CC 15 Yes NE [22]
Mature autologous DC pulsed with full-length HPV-16 or -18 E7
oncoprotein, followed by subcutaneous low doses of human
recombinant interleukin-2
Pilot Recurrent CC 4 Yes NE [23]
Escalating doses of mature autologous DC pulsed with full-length HPV-
16/18 E7 oncoprotein and keyhole limpet hemocyanin
1 Stage IB/IIA CC 10 Yes NE [24]
HPV-16 E6 (18–26) or E7 (12–20) peptide pulsed on pre-immature
dendritic cells
Pilot, R Advanced CC 32 Yes NE [29]
Cisplatin chemotherapy alone or with dendritic cell-cytokine-induced
killer cells
2, R CC 79 Yes Yes [32]
Tumor-infiltrating T-cells selected when possible for HPV E6 and E7
reactivity (HPV-TILs)
2 Advanced CC 9 Yes Yes [37]
Peptide–protein-based vaccines
HPV-16 E6 combined with or separated from HPV-16 E7 overlapping
long peptides in Montanide ISA-51 adjuvant
1 Advanced CC 35 Yes NE [44]
HPV-16-synthetic long peptide vaccine consisting of a mix of 13 HPV-16
E6 and HPV-16 E7 overlapping long peptides in Montanide ISA-51
adjuvant
2 Advanced or recurrent HPV-
16-positive gynecological
carcinoma
20 Yes No [45]
Four peptides covering the HPV-type-16 E6 protein and Candida skin
test reagent as adjuvant (PepCan)
1 CIN2-3 24 Yes NE [46]
Multiple peptides cocktail vaccine; each peptide was mixed in
Montanide ISA-51 adjuvant
2 Advanced CC/ ovarian cancer 67 Yes Yes [47]
Escalating doses of two HPV-16 E7 peptides and one helper peptide
emulsified in Montanide ISA 51 adjuvant
1/2 HLA-A*0201 positive with
HPV-16 positive CC
19 NE Yes [48]
Escalating doses of 9-amino acid peptide from amino acids 12–20
encoded by the E7 gene emulsified with incomplete Freund’s
adjuvant
1 HPV-16 and HLA-A2 positive
high-grade cervical or
vulvar
intraepithelial neoplasia
18 Yes NE [49]
HLA-restricted HPV-16 E7 epitope adjuvated with very small size
proteoliposomes
FiH HPV-16 and HLA-A2 positive
high grade CIN
7 Yes NE [50]
Mixture of HPV-16 E6E7 fusion protein and ISCOMATRIX adjuvant 1, R CIN 1–3 31 Yes NE [52]
Escalating doses of HPV-16 L2, E6, and E7 as a single fusion protein (TA-
CIN)
1, R Healthy volunteers 40 Yes NE [53]
Fusion protein (PD–E7) comprising a mutated HPV-16 E7 linked to the
first 108 amino acids of Haemophilus influenzae protein D,
formulated in the GlaxoSmithKline Biologicals adjuvant AS02B
1/2 CIN 1,3 7 Yes NE [54]
Fusion protein containing an M. bovis BCG heat shock protein (Hsp65)
covalently linked to the entire sequence of HPV-16 E7 (SGN-00101)
2 CIN3 72 NE Yes [55]
Fusion protein containing an M. bovis BCG heat shock protein (Hsp65)
covalently linked to the entire sequence of HPV-16 E7 (SGN-00101)
2 CIN3 21 Yes Yes [56]
Nucleic acid-based vaccines
Escalating doses of ZYC101 1 HPV-16 and HLA-A2 positive
CIN 2/3
15 Yes NE [59]
ZYC101a, including HPV-16/18 E6- and E7-derived CTL epitopes 2, R CIN2/3 127 NE Only in
younger
patients
[60]
Escalating doses of DNA plasmid expressing HPV-16E7 mutated at aa 24
and 26, linked to sequences coding for Sig and for HSP70 [pNGVL4a-
Sig/E7(detox)/HSP70]
1 HPV-16 positive CIN2/3 15 Yes NE [61]
DNA vaccine expressing HPV-16 E7 (DNAE7) followed by a recombinant
vaccinia boost expressing HPV-16 and HPV-18 E6 and E7 (rVacE6E7;
TA-HPV)
1 HPV-16 positive CIN2/3 12 Yes NE [62]
Two DNA plasmids encoding optimized synthetic consensus E6 and E7
genes of HPV-16 and HPV-18 (VGX-3100)
2, R HPV-16 or HPV-18 positive
CIN2/3
107 Yes Yes [63]
Live vector-based vaccines
Vaccinia vector-based vaccine expressing modified forms of HPV-16 and
-18 E6 and E7 proteins (TA-HPV)
2 Stage IB–IIA CC 29 Yes NE [65]
Live recombinant vaccinia virus expressing HPV-16 and -18 E6/E7
proteins
1/2 Advanced CC 8 Yes NE [66]
Modified Vaccinia Ankara virus, an attenuated replicon-deficient vaccinia
strain, expressing E2 (MVA-E2)
1/2 CIN2/3 34 Yes Yes [67]
Suspension of MVATG8042 vector particles consisting of an attenuated
recombinant vaccinia virus, modified vaccinia virus of Ankara,
containing the sequence coding for the modified E6 and E7 early
genes of HPV-16 and human interleukin-2 gene (TG4001)
2 HPV-16 positive CIN2/3 21 Yes Yes [68]
Recombinant adenovirus-p53 (rAd-p53) combined with chemotherapy 2, R Stage IIb2-IV CC 40 NE Yes [71]
Escalating doses of live-attenuated Listeria monocytogenes (Lm) vaccine
that secretes the HPV-16 E7 antigen fused to a non-hemolytic
fragment of the Lm protein listeriolysin O (LLO), Lm-LLO- E7
2 Advanced CC 15 NE NE [74]
Live attenuated Listeria monocytogenes (Lm) bioengineered to secrete a
HPV-16-E7 fusion protein targeting HPV transformed cells (ADXS11-
001)
2, R Advanced CC 110 NE Yes [75]
Abbreviations: CC, cervical cancer; CIN, cervical intraepithelial neoplasia; CTL, cytotoxic T-lymphocyte; DC, dendritic cell; FiH, first-in-human; N, number; NE, not
evaluable; R, randomized.
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Adoptive T-cell therapy (ACT)
ACT allows a more rigorous control on the magnitude of the
targeted response than tumor vaccination strategies. T-cells of
a desired specificity and phenotype can be identified and
expanded in vitro to obtain following reinfusion a number of
antigen-specific T-cells that is 10-fold greater than those
reachable by using current therapeutic vaccines regimens
alone [36]. Recently, this ACT approach was utilized in che-
motherapy-refractory metastatic cervical cancer epithelial
malignancy. Tumor-infiltrating T-cells were collected from
patients, expanded, and selected for HPV reactivity (HPV-
TILs). Single infusion of these TILs induced objective responses
in three out of nine patients and the presence of TILs in
peripheral blood 1 month after treatment was associated
with clinical response [37]. Although this technique cannot
be easily performed, it may represent a dramatic improvement
of advanced cervical cancer treatment where even new biolo-
gical therapies failed to ameliorate the prognosis of these
patients.
Peptide-protein-based vaccines
Synthetic peptide vaccines can be divided into two groups:
synthetic long peptides and specific epitope (short) peptides.
Peptide-based therapeutic vaccines have the advantages of
stability, safety and easy production [38], even if the immuno-
genity is low, and there is the need of identifying specific
epitopes of HPV antigens for different HLA haplotypes [39].
Synthetic long peptides-based vaccines were largely tested
in experimental models, and some of them tested in clinical
trials [40]. The use of synthetic long peptides has several
advantages over short peptides. Notably, it does not require
patient selection based on MHC profile. Recently, the interest
toward synthetic long peptides-based vaccines has been
strengthened because of the broad range of antigenic epi-
topes through inclusion of immunogenic peptides or peptides
which guide CD4 + T-helper or CD8+ cytotoxic responses.
Results in animal models showed immunologic responses
and HPV-16 tumors eradication in vaccinated animals [41,42].
An interesting study in high-grade HPV-16 related vulvar
intraepithelial neoplasia (VIN), where the spontaneous regres-
sion is less than 1.5%, was recently published and the authors
investigated the immunogenicity and the efficacy of a syn-
thetic long-peptide vaccine in 20 women. They received multi-
ple three to four doses of vaccine (a mixture of long peptide
from HPV-16 oncoprotein E6 and E7 in incomplete Freund’s
adjuvant). Toxicity was low, and at 12 months of follow-up 9
patients over 19 showed complete response (47%), which was
maintained at 24 months. Moreover, patients with complete
response had a stronger immunologic response [43]. A phase I
trial with synthetic long peptide vaccine in advanced cervical
cancer showed low toxicity and high immunogenicity [44].
Consequently, the HPV-16-synthetic long peptide vaccine
was tested in 20 advanced/recurrent cervical cancer patients
in a phase II trial, and HPV-16-specific T-cell response was
analyzed. In 13 evaluable patients, a HPV-16-specific T-cell
Table 2. Relevant ongoing clinical trials with therapeutic vaccines for cervical
pre-neoplastic lesions and cervical cancer.
Therapeutic agent Phase Disease Trial ID
Peptide–protein-based vaccines
Therapeutic human
papilloma virus 16 (HPV-
16) E6/E7 long peptides
vaccine (ISA101) at
different doses with or
without IFN-α as
combination therapy
with carboplatin and
paclitaxel
1/2 HPV-16 positive
advanced or recurrent
cervical cancer
NCT02128126
HPV-16 E6 peptides
combined with Candida
skin testing reagent
called Candin® (PepCan)
2 High grade CIN NCT02481414
Escalating doses of
R-enantiomer of 1,2-
dioleoyl-3-
trimethylammonium-
propane chloride plus
Peptides from HPV-16
E6 and E7 (PDS0101)
1 Female subjects with
high-risk HPV
infection and biopsy-
proven CIN1
NCT02065973
Escalating dose of a
vaccine consisting of
four HPV-16 E6 peptides
in combination with
Candin
1 High grade CIN NCT01653249
Tumor specific potentiated
vaccine therapy using
cyclophosphamide
combined epitope
peptide cocktail (five
peptide vaccines of
KOC1, TTK, CO16,
DEPDC1, MPHOSPH1)
1 Progressive or relapsed
solid tumors including
cervical carcinoma
NCT00676949
SGN-00101 (HSP-E7) fusion
protein
2, R High grade CIN NCT00054041
Nucleic acid-based vaccines
VB10.16 immunotherapy
(DNA vaccine)
1/2 High grade CIN NCT02529930
HPV-16-specific
therapeutic DNA-
vaccinia vaccination in
combination with
topical imiquimod
1 HPV-16 related CIN3 NCT00788164
pnGVL4a-CRT/E7 (Detox) 1 HPV-16 related CIN2/3 NCT00988559
INO-3112 (VGX-3100 and
INO-9012) delivered
intramuscularly by
electroporation
1/2 HPV-16 or -18 related
invasive cervical
carcinoma
NCT02172911
Naked plasmid coding for
HPV-16 and -18 E6/E7
(GX-188E) administered
i.m. by electroporation
1 HPV-16 or -18 related
CIN3
NCT01634503
Naked plasmid coding for
HPV-16 and -18 E6/E7
(GX-188E) administered
i.m. by electroporation
2, R HPV-16 or -18 related
CIN3
NCT02139267
Change of immunogenicity
and lesion condition in
subjects who have
enrolled and
participated
NCT02139267 trial
Obs Subjects who
participated
NCT02139267 trial
NCT02411019
Live vector-based vaccines
Attenuated Live Listeria
Encoding HPV-16 E7
Vaccine ADXS11-001
2 Persistent or recurrent
cervical carcinoma
NCT01266460
ADXS11-001 administered
following
chemoradiation as
adjuvant treatment
3 High-risk, locally
advanced cervical
carcinoma
AIM2CERV
CIN: cervical intraepithelial neoplasia; Obs: observational; R: randomized.
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response was recorded after two to four vaccinations, and
patients failing to have a specific response also did not
develop immunity against other antigens, suggesting a
decreased T-cell immunocompetence. Unfortunately, although
the vaccine was well tolerated, the induced specific immune
response did not result in regressions of the tumor [45]. A
phase I/II study with therapeutic HPV-16 long peptide vaccine
(ISA101) at different doses with or without IFN-alpha in com-
bination with carboplatin and paclitaxel in advanced cervical
cancer (NCT02128126) is ongoing to determine safety and
immunomodulating effects.
A phase I dose-escalation trial of a peptide-based HPV
therapeutic vaccine with Candida skin test reagent as adjuvant
(PepCan) was carried out in 24 CIN2/3 patients, showing very
low toxicity, a satisfactory regression rate, and a significant
immune response [46]. The phase II is ongoing
(NCT02481414). HPV-16 E6/E7-derived epitopes are being
investigated as liposome-encapsulated in CIN (NCT02065973).
A phase I study is testing a HPV vaccine consisting of four
HPV-16 peptides in combination with Candin (purified extract
from Candida Albicans) to determine optimal dose, immuno-
genicity, maximum tolerated dose in women with HSIL lesions
(NCT01653249).
A phase II study of multiple peptides cocktail vaccine for
advanced cervical and ovarian patients was recently presented
at American Society of Clinical Oncology Meeting, in May 2015
[47]. In 21 cervical cancer patients they observed 2 complete
responses, a median overall survival of 15.4 months and a
good tolerability. A phase I trial is evaluating safety and effi-
cacy of cyclophosphamide combined with specific epitope
cocktail and IL-2 for advanced cancers including cervical can-
cers (NCT00676949).
The use of epitope-specific short peptides-based vaccines
aims at ensuring precisely targeted cytotoxic T-lymphocyte
(CTL) responses through immunization with specific epitopes,
and it is well known how linear short peptide epitopes can
induce cytotoxic responses. This kind of vaccine is restricted to
patients of a given HLA type; thus, preliminary HLA typing is
Figure 1. Methodologies for production and delivery of HPV therapeutic vaccines as well as their immunological activity.
Abbreviations: Ag, antigen; DCs, dendritic cells; Treg, regulatory T-cell; Th, T helper cell.
EXPERT REVIEW OF VACCINES 1331
needed before vaccination. Some epitope-specific therapeutic
HPV vaccines have been tested in clinical trials, with low
clinical responses in VIN or CIN [48,49], even employing new
delivery system [50], while other phase I trials are ongoing also
in other diseases (NCT00257738; NCT01653249).
The advantage of protein-based vaccines over peptide-
based is that the former can circumvent the MHC specificity
limitation. However, a potential disadvantage of proteins vac-
cine is that they may induce antibody responses rather than
CTL responses. To avoid this disadvantage and to improve
immunogenicity, adjuvant have been added into vaccines
and/or proteins for therapeutic vaccination have been linked
to molecules able to better induce APC presentation.
Various protein vaccines have moved to clinical trials. Few
protein-based vaccines have reached the clinical phase [17,51].
Immunization with HPV-16 E6/E7 fusion protein mixed with
the ISOMATRIX adjuvant was shown to be safe and immuno-
genic in a Phase I study. In addition, enhanced CD8+ T-cell
responses to both E6 and E7 were recorded in vaccinated
patients versus placebo recipients [52]. A protein vaccine,
TA-CIN, consisting of a fusion of HPV-16 L2, E6, and E7, was
proved to be safe and able to elicit humoral response in all the
treated women and cellular (T-cell specific) immunity in a
subset of them [53]. A mutated HPV-16 E7 fused to part of
Haemophilus influenzae protein D, mixed with adjuvant AS02B
(GSK proprietary formulation) has been evaluated in and was
shown to induce significant E7-specific CTL responses in Phase
I/II clinical trials on CIN1–CIN3 [54]. A complete regression was
reported in 22% of CIN3 patients in a phase II trial [55]
employing HspE7 (a fusion protein consisting of HPV-16 E7
and Hsp65 from Mycobacterium Bovis – SNG00101). Another
trial using the same vaccine in 20 CIN3 patients reported 35%
of complete regression and correlation with immune response
[56]. A phase II randomized (vs. standard surgical treatment)
study with SGN00101 (HSP-E7) fusion protein is being tested
in women with CIN3 (NCT00054041).
Nucleic acid-based vaccines
DNA-based vaccines
DNA-based vaccines are safe, can be easily produced, and are
capable of inducing both CTL and Th immunity, and also B-cell
immunity; moreover, they can be administered repeatedly for
long-term protection, even if they lack in inducing potent
antigen specific cellular response because of immune toler-
ance against self-antigens [57]. To increase immunogenicity,
encoding xenogenic version of antigens, fusions of antigens
with T-cells activating molecules, priming with DNA vectors
followed by boosting with viral vectors, or the use of immu-
nomodulators have been investigated.
A DNA plasmid (ZYC101) was tested in a phase I trial in 12
patients with anal inthraepithelial neoplasia, with a broad
antigen-specific immune response [58]. The same vaccine
was tested in 15 CIN2/3 patients, with five patients showing
complete histological regression [59]. More interestingly, the
new form of the vaccine (ZYC101a, including HPV-16/18 E6-
and E7-derived CTL epitopes), was employed in a randomized,
double blind, phase II trial, enrolling 127 CIN2/3 patients, with
a trend in the experimental arm for complete regression, and a
statistically significant difference in very young patients [60]. A
phase I–II ongoing study is testing safety and immunogenicity
of a DNA vaccine, VB10.16 in women with CIN3
(NCT02529930). Another DNA vaccine targeting E7, pNGVLa-
Sig/E7(detox)-Hsp70, was employed in a phase I–II trial in
CIN2/3 patients. The E7 sequence was fused to a chaperone
(Hsp70 from Mycobacterium tuberculosis) to enhance APC
uptake, processing and presentation. Significant immune
response was observed in eight patients, and a complete
regression was observed in three patients [61]. More recently
a phase I trial with sequential pNGVLa-Sig/E7(detox)-Hsp70
with a recombinant vaccine virus encoding E6/E7 fusion pro-
tein, with or without imiquimod, an immunomodulator, was
tested in 12 patients with CIN3, and five of them showed
complete regression [62]. The study is ongoing
(NCT00788164). Another ongoing study is testing different
routes of administration of pnGVL4a-CRT/E7 (Detox) in
patients with CIN2/3 (NCT00988559).
Recently, a mixture of two plasmids encoding HPV-16/18 E6/
E7 antigens, VGX-3100 vaccine, administered by electroporation,
is being tested in phase I–II trials. A phase IIb randomized,
double-blind placebo controlled trial (NCT01304524) tested
VGX-3100 in CIN2/3 patients. Among 107 evaluable patients, 53
of the treated patients (49.5%) and 11 (30.6%) of the placebo arm
showed complete regression (p = 0.034). Toxicity was low, with
mild injection-site reactions in almost all the patients, and
erythema significantly more common in the vaccine arm, so
the VGX-3100, inducing both T-cell and antibody response to
E6 and E7, is the first therapeutic vaccine to show efficacy against
HPV-16 and HPV-18 related CIN2/3 [63]. This study represents a
proof of principle for a therapeutic approaches distinct from
surgery. Another study is ongoing, testing VGX-3100, adminis-
tered i.m. by electroporation with IL-2-12-coding construct (INO-
9012) and optionally combined with radiotherapy
(NCT02172911). A naked plasmid coding for HPV-16 and 18 E6/
E7 (GX-188E) and for fms-like tyrosine kinase-3 ligand (FLT3LG)
administered i.m. by electroporation is being tested for safety in
a phase I study in patients with CIN3 (NCT01634503), and with
different doses in a phase I–II randomized study in patients with
HPV-16 or 18 related CIN3 (NCT02139267). Another ongoing
study with the same vaccine is a prospective, multicenter, obser-
vational, follow-up clinical study to determine recurrence of CIN
and long-term safety (NCT02411019).
RNA-based vaccines
RNA-based vaccines are created using naked RNA replicons
derived from alpha-viruses to promote antigen-specific
immune response. The replicon-based vectors can replicate
in a wide range of cell types, with different expression of
antigens. These RNA replicons are less stable than DNA. A
combined approach with DNA-launched RNA replicon, termed
‘suicidal’ DNA was developed for HPV vaccine in preclinical
models [64]. The newest mRNA-based vaccines have also been
developed and the RNActive® vaccine platform from CureVac
(Tübingen, Germany) is in clinical trials for prostate and non-
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small cell lung cancer. RNActive vaccines were well tolerated
and induced long lasting, humoral and cellular immune
responses. However, information about clinical testing on
HPV-associate cancers is lacking.
Live vector-based vaccines
Viral vector vaccines
Viral vector-based vaccines have high infection efficiency and
high antigens expression, encoded by the virus in the infected
cells. Many viral vectors, such as adenoviruses, alphaviruses,
vaccinia viruses, fowlpox viruses have been tested, and the
most interesting are vaccinia virus-based vaccines [65,66]. The
first clinical trial of a live recombinant vaccinia virus expressing
HPV-16 and -18 E6/E7 proteins was a phase I–II trial where
eight advanced cervical cancer patients received a single dose
of vaccine. No significant side-effects were observed, and 3
out of 8 patients had an HPV-specific antibody response [66].
A study tested a vaccinia vector-based vaccine expressing
modified forms of HPV-16 and -18 E6 and E7 proteins (TA-
HPV) in 29 patients with stage IB-IIA prior surgery, and specific
CTLs and serologic response were found in a subset of
patients [65]. Further positive results were observed in VIN
and in VAIN.
The MVA-E2 viral-based vaccine is a modified Vaccinia
Ankara virus, an attenuated replicon-deficient vaccinia
strain, expressing E2, and a phase I–II study in 34 CIN2/3
patients showed complete regression in 20 patients, with
the development of HPV- specific antibodies [67]. In
another study 21 patients with CIN2/3 were treated with
TG4001, a modified vaccinia Ankara viral vector encoding
HPV-16 E6/E7 and IL-2, and 10 (48%) patients had clinical
response at month 6, with seven complete responses, war-
ranting further development of clinical trials [68]. A rando-
mized phase II study (NCT01022346) is testing TG4001, and
preliminary results reported significant differences between
vaccine and placebo in a press release [69]. Twelve patients
with HPV-16 associated CIN2/3 have been treated with
peripheral vaccination with a heterologous DNA prime-
recombinant vaccinia vector-based boost vaccination regi-
men before surgical resection in a phase I study. The
schema included two priming vaccination with a DNA vac-
cine expressing HPV-16 E7, following by a recombinant
vaccinia boost expressing HPV-16 and -18 E6/E7. Three
dose levels have been evaluated (cohort 1, 2, 3). Toxicity
was low, mostly consisting in injection site reactions, and
one out of three patients in each of the one and two
cohorts had complete regression of the lesion at surgery,
whereas at the highest dose level, three out of six patients
had complete regression [62].
Adenoviral vector (rAd)-based vaccines showed immunolo-
gical response in preclinical studies, but to date no therapeutic
effects have been observed [70]. Recombinant adenovirus-p53
combined with chemotherapy was tested in a phase II study
presented at American Society of Clinical Oncology May 2013
[71]. Forty patients received chemotherapy plus rAd-p53 or
chemotherapy alone; the response rate was 95% versus 75%,
and the overall 1-year survival rates were 90% and 65%,
respectively, without serious adverse events related to
rAD-p53.
Bacterial vector vaccines
Several bacterial vectors have been tested as therapeutic vac-
cines, such as Listeria monocytogenes, Lactobacillus plan-
tarum, Lactococcus lactis, with the Listeria-based being the
most extensively studied [72]. A phase I trial tested the toler-
ability of the Listeria-based vaccine (Lm-LLO-E7) in 15 patients
with advanced cervical cancer, with some severe (grade 3)
reactions in 40% of the patients, and 1 partial response [73].
The results of a prospective randomized trial employing a
Listeria Monocytogenes-based vector vaccine (ADXS11-001) in
110 advanced cervical cancer patients were presented at the
ASCO meeting in June 2014. Patients were randomized to
three doses of vaccines or four doses with weekly cisplatin.
Final 12-month’s overall survival was 36%, 18-month’s overall
survival was 28%, response rate was 11% with six complete
responses, and the authors reported 2% of grade 3 adverse
events. No benefit was observed from the addition of cisplatin
[74]. The NRG0265 phase II study with multiple doses of
ADXS11-001 is currently ongoing [75, NCT01266460], without
cisplatin, and preliminary results showed in 26 evaluable
patients receiving at least one dose a 12-month overall survi-
val of 38.5% [76]. Other trials with ADXS11-001 are ongoing in
CIN2/3 or cervical cancer, and an international phase III study
(AIM2CERV) of ADXS11-001 as adjuvant treatment of high-risk,
locally advanced cervical cancer is under development in
collaboration with Gynecologic Oncology Group.
Conclusions
Immunotherapy is one of the most promising strategies for
cancer treatment. In cervical cancer and its precursors, the use
of therapeutic vaccines was associated with the regression of
premalignant lesions and some clinical benefit in cancer
patients. To mitigate the immunosuppressive effects of cancer
microenvironment, combinatorial approaches, such as radio-
therapy, chemotherapy, immunomodulators, immune check-
point inhibitors, are being tested in cervical cancer patients.
Indeed, although chemotherapy and immunotherapy have
not shown to be curative as single treatment modalities in
the advanced setting, growing evidence suggests a synergistic
activity with immunological approaches [77].
The available literature data suggest that therapeutic vac-
cines for pre-neoplasia and cancer of cervix are reality (i.e.
synthetic long peptide or electroporated DNA vaccines). The
improvement of all therapeutic strategies and the identifica-
tion of their optimal combination opens a new scenario in the
treatment of cervical cancer and pre-neoplastic lesions.
Expert commentary
About 20% of human cancers are linked to infectious diseases
and among them one-third of tumors are caused by HPV. The
observation that HPVs related to cancer express two main
oncogenes, i.e. E6 and E7, that are essential for transformation
and maintenance of transformed status, makes these
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oncogenes ideal targets of cancer immunotherapy. E6 and E7
can be considered the best tumor-associated antigen, and
many different therapeutic vaccines have been produced
and employed in clinical trials for cervical cancer and pre-
neoplastic lesions. Some of these trials have demonstrated
not only safety and immunological responses to therapeutic
HPV vaccines but also their clinical efficacy. Thus, HPV thera-
peutic vaccines must be regarded as a therapeutic option
together with other currently available therapies.
Five-year view
The HPV-E6 and -E7 antigens represent the ideal targets for
therapeutic vaccines in premalignant and malignant cervical
lesions. Looking to the future, applying new technologies (i.e.
omics) to better define HPV infections that evolve to CIN and
cervical cancer could enhance the efficacy of the vaccines by
improving target selection and by reducing unwanted side
effects. Since at present effective treatments are lacking
mainly in advanced cervical disease, the next 5 years will be
focused also on how to combine therapeutic vaccination with
other conventional treatment strategies, such as chemother-
apy, radiation, biological agents, and other immunologic
approaches. In particular, check-point inhibitors, empowering
any ongoing anti-cancer immune response that might have
been too weak or exhausted, have shown extremely encoura-
ging clinical activity. Monoclonal antibodies (mAb) interfering
with CTLA-4-CD80/86, PD-1/PD-L1, TIM-3-GAL9, and LAG3-
MHC-II belong to this category of check-point inhibitors and
some of them are already US FDA approved for melanoma
cancer treatment [20]. As the role of immunotherapy for the
treatment of premalignant lesions and cervical cancer con-
tinues to evolve, several clinical trials are ongoing and in
development, and further studies on the immune cellular
and molecular mechanisms of action and on preclinical mod-
els are needed to better elucidate immunological background
and to explore the optimal integration among treatments and
combination immunotherapies. For the next 5 years, the com-
bination or sequential application of immunotherapic agents
will be the front line in the battle against cancer, including
cervical cancer and its precursor. However, toxicities and pro-
hibitive costs of immunostimulatory mAb are serious limits to
combination immunotherapy and researches must be also
focused on overcoming these obstacles.
Key issues
● HPVs linked to cancer express two main oncogenes, E6 and
E7, that represent an excellent target for cancer
immunotherapy.
● Many therapeutic vaccines have been tested in order to
increase viral specific immune responses, showing an
acceptable safety profile and clinical efficacy.
● In a phase II trial, patients with chemotherapy-refractory
metastatic cervical cancer epithelial malignancy were trea-
ted with adoptive T-cell therapy. Despite this technique is
technically difficult, it showed some clinical activity.
● In patients with HPV16 or HPV18 positive CIN, a phase II
randomized trial showed clinical activity of a nucleic acid-
based vaccine.
● Multiple trials involving peptide-protein-based vaccines and
live-vector based vaccines demonstrated that this
approaches may be effective in CIN as well as in advanced
cervical cancer patients.
● HPV therapeutic vaccines is one of the most promising
strategies for cancer treatment, showing regression of pre-
malignant cervical lesions and some clinical activity in cer-
vical cancer patients.
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